Compared with the prior quarter’s emphasis on a strong 2025 close ("2025 was a remarkable year for Adaptive" (CEO Robins, Q4 call)), this call leaned more on in-year acceleration and specificity ...

Q1 2026 Management View "We reported revenue in the first quarter of just over $200 million, coming within our Q1 revenue guidance range" (President, CEO & Director Samraat Raha). "We delivered ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma. A new ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "Global MRD Testing Market: Focus on Technology, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2025" report has ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

Minimal residual disease was “strongly” associated with overall survival at the patient level, researchers reported. Minimal residual disease (MRD) is “a credible intermediate endpoint” for some ...